KEAP1/NFE2L2 Mutations of Liquid Biopsy as Prognostic Biomarkers in Patients With Advanced Non-Small Cell Lung Cancer: Results From Two Multicenter, Randomized Clinical Trials

KEAP1/NFE2L2 Mutations of Liquid Biopsy as Prognostic Biomarkers in Patients With Advanced Non-Small Cell Lung Cancer: Results From Two Multicenter, Randomized Clinical Trials

PurposeThe KEAP1-NFE2L2 (Kelch-like ECH-associated protein 1 (KEAP1)-Nuclear factor (erythroid-derived 2)-like 2 (NFE2L2)) mutations are associated with resistance to chemotherapy or immunotherapy in non-small cell lung cancer (NSCLC). Conversely, it has been reported that NFE2L2 mutations potentiat...

Full description

Bibliographic Details
Main Authors: Hongyuan Zhu, Daipeng Xie, Yunfang Yu, Lintong Yao, Bin Xu, Luyu Huang, Shaowei Wu, Fasheng Li, Yating Zheng, Xinyi Liu, Wenzhuan Xie, Mengli Huang, Hao Li, Shaopeng Zheng, Dongkun Zhang, Guibin Qiao, Lawrence W. C. Chan, Haiyu Zhou
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-07-01
Series:Frontiers in Oncology
Subjects:
prognostic
KEAP1/NFE2L2
non-small cell lung cancer
immunotherapy
chemotherapy
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.659200/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.659200/full

Similar Items